GSK’s Arexvy associated with reductions in certain RSV-related risks including heart attack, stroke and severe flare-ups of COPD and asthma, real world study shows
Reduction observed in RSV-related hospitalisations in adults aged ≥60 yearsGlaxoSmithKline plc (GSK)">Weiter zum vollständigen Artikel bei GlaxoSmithKline plc (GSK)
Quelle: EN, GlaxoSmithKline